$106.73
0.970.92%
At close: -
$107.41
0.680.64%
After Hours: Apr 25, 4:03 PM EDT
Comments
Loading...
Neurocrine Biosciences Analyst Ratings and Price Targets | NASDAQ:NBIX | Benzinga
Neurocrine Biosciences Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Neurocrine Biosciences Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Evercore ISI Group
HC Wainwright & Co.
Needham
RBC Capital
UBS
1calculated from analyst ratings
Analyst Ratings for Neurocrine Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/24/2025 | Buy Now | — | Evercore ISI Group | Cory Kasimov69% | $190 → $185 | Maintains | Outperform | Get Alert |
| 04/22/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein56% | $185 → $168 | Maintains | Buy | Get Alert |
| 04/15/2025 | Buy Now | — | Needham | Ami Fadia53% | → $138 | Upgrade | Hold → Buy | Get Alert |
| 04/14/2025 | Buy Now | — | RBC Capital | Brian Abrahams49% | $138 → $137 | Upgrade | Sector Perform → Outperform | Get Alert |
| 04/04/2025 | Buy Now | — | UBS | Ashwani Verma42% | $154 → $137 | Maintains | Buy | Get Alert |
| 03/26/2025 | Buy Now | — | JP Morgan | Anupam Rama58% | $183 → $184 | Maintains | Overweight | Get Alert |
| 03/07/2025 | Buy Now | — | Morgan Stanley | Jeffrey Hung50% | $185 → $150 | Assumes | → Overweight | Get Alert |
| 02/24/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein56% | $185 → $185 | Reiterates | Buy → Buy | Get Alert |
| 02/21/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein56% | $185 → $185 | Reiterates | Buy → Buy | Get Alert |
| 02/10/2025 | Buy Now | — | Guggenheim | Yatin Suneja49% | $165 → $163 | Maintains | Buy | Get Alert |
| 02/10/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein56% | $190 → $185 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | — | RBC Capital | Brian Abrahams49% | $154 → $148 | Maintains | Sector Perform | Get Alert |
| 02/07/2025 | Buy Now | — | Wedbush | Laura Chico45% | $157 → $147 | Maintains | Outperform | Get Alert |
| 02/07/2025 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni39% | $172 → $163 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein56% | $190 → $185 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | Hold → Hold | Get Alert |
| 02/07/2025 | Buy Now | — | B of A Securities | Tazeen Ahmad55% | $184 → $179 | Maintains | Buy | Get Alert |
| 02/04/2025 | Buy Now | — | Morgan Stanley | Jeffrey Hung50% | $170 → $185 | Maintains | Overweight | Get Alert |
| 01/30/2025 | Buy Now | — | UBS | Ashwani Verma42% | $162 → $176 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | — | UBS | Ashwani Verma42% | $142 → $162 | Maintains | Buy | Get Alert |
| 12/23/2024 | Buy Now | — | Piper Sandler | David Amsellem70% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 12/23/2024 | Buy Now | — | Barclays | Carter Gould59% | $160 → $165 | Maintains | Overweight | Get Alert |
| 12/20/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | Hold → Hold | Get Alert |
| 12/16/2024 | Buy Now | — | Wedbush | Laura Chico45% | $148 → $148 | Reiterates | Outperform → Outperform | Get Alert |
| 12/16/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein56% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
| 11/01/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein56% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
| 10/30/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
| 10/29/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
| 10/17/2024 | Buy Now | — | BMO Capital | Evan Seigerman64% | $128 → $114 | Maintains | Market Perform | Get Alert |
| 10/10/2024 | Buy Now | — | Raymond James | Danielle Brill42% | → $155 | Reinstates | → Outperform | Get Alert |
| 10/08/2024 | Buy Now | — | RBC Capital | Brian Abrahams49% | $133 → $133 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 10/04/2024 | Buy Now | — | RBC Capital | Brian Abrahams49% | $136 → $133 | Maintains | Sector Perform | Get Alert |
| 09/16/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan68% | $155 → $155 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | — | Barclays | Carter Gould59% | $180 → $160 | Maintains | Overweight | Get Alert |
| 08/29/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan68% | $170 → $155 | Maintains | Overweight | Get Alert |
| 08/29/2024 | Buy Now | — | BMO Capital | Evan Seigerman64% | $142 → $128 | Maintains | Market Perform | Get Alert |
| 08/29/2024 | Buy Now | — | Piper Sandler | David Amsellem70% | $131 → $159 | Upgrade | Neutral → Overweight | Get Alert |
| 08/29/2024 | Buy Now | — | RBC Capital | Brian Abrahams49% | $143 → $136 | Maintains | Sector Perform | Get Alert |
| 08/29/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein56% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
| 08/29/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
| 08/19/2024 | Buy Now | — | Jefferies | Akash Tewari43% | $177 → $189 | Maintains | Buy | Get Alert |
| 08/07/2024 | Buy Now | — | JP Morgan | Anupam Rama58% | $173 → $181 | Maintains | Overweight | Get Alert |
| 08/05/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein56% | $160 → $190 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | — | RBC Capital | Brian Abrahams49% | $136 → $143 | Maintains | Sector Perform | Get Alert |
| 08/02/2024 | Buy Now | — | Guggenheim | Yatin Suneja49% | $170 → $180 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | — | Citigroup | David Hoang35% | $150 → $158 | Maintains | Neutral | Get Alert |
| 08/02/2024 | Buy Now | — | Oppenheimer | Jay Olson61% | $216 → $219 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | — | Barclays | Carter Gould59% | $169 → $180 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | — | Baird | Brian Skorney58% | $157 → $180 | Maintains | Outperform | Get Alert |
| 08/01/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
| 07/25/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan68% | $155 → $155 | Reiterates | Overweight → Overweight | Get Alert |
| 07/25/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
| 07/12/2024 | Buy Now | — | Morgan Stanley | Jeffrey Hung50% | $160 → $170 | Maintains | Overweight | Get Alert |
| 07/10/2024 | Buy Now | — | JP Morgan | Anupam Rama58% | $169 → $173 | Maintains | Overweight | Get Alert |
| 06/12/2024 | Buy Now | — | Morgan Stanley | Jeffrey Hung50% | $160 → $160 | Maintains | Overweight | Get Alert |
| 05/29/2024 | Buy Now | — | Wedbush | Laura Chico45% | $152 → $152 | Reiterates | Outperform → Outperform | Get Alert |
| 05/28/2024 | Buy Now | — | UBS | Ashwani Verma42% | $174 → $193 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | — | Evercore ISI Group | Cory Kasimov69% | → $175 | Initiates | → Outperform | Get Alert |
| 05/03/2024 | Buy Now | — | Citigroup | David Hoang35% | $140 → $150 | Maintains | Neutral | Get Alert |
| 05/02/2024 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni39% | $154 → $164 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | — | Guggenheim | Yatin Suneja49% | $164 → $170 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | — | Barclays | Carter Gould59% | $150 → $169 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | — | BMO Capital | Evan Seigerman64% | $129 → $138 | Maintains | Market Perform | Get Alert |
| 05/02/2024 | Buy Now | — | Oppenheimer | Jay Olson61% | $200 → $216 | Maintains | Outperform | Get Alert |
| 05/02/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein56% | $150 → $160 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
| 05/01/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
| 04/24/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein56% | $150 → $150 | Reiterates | Buy → Buy | Get Alert |
| 04/24/2024 | Buy Now | — | Wells Fargo | Mohit Bansal70% | $140 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/24/2024 | Buy Now | — | Oppenheimer | Jay Olson61% | $200 → $200 | Maintains | Outperform | Get Alert |
| 04/23/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
| 04/17/2024 | Buy Now | — | Wedbush | Laura Chico45% | $147 → $147 | Reiterates | Outperform → Outperform | Get Alert |
| 04/10/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan68% | → $155 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | Buy Now | — | JP Morgan | Anupam Rama58% | $148 → $158 | Maintains | Overweight | Get Alert |
| 03/13/2024 | Buy Now | — | Oppenheimer | Jay Olson61% | $170 → $200 | Maintains | Outperform | Get Alert |
| 02/23/2024 | Buy Now | — | JP Morgan | Anupam Rama58% | $154 → $148 | Maintains | Overweight | Get Alert |
| 02/08/2024 | Buy Now | — | Citigroup | David Hoang35% | $141 → $140 | Maintains | Neutral | Get Alert |
| 02/08/2024 | Buy Now | — | Mizuho | Uy Ear62% | $116 → $140 | Maintains | Neutral | Get Alert |
| 02/08/2024 | Buy Now | — | Wells Fargo | Mohit Bansal70% | $127 → $140 | Maintains | Equal-Weight | Get Alert |
| 01/25/2024 | Buy Now | — | Goldman Sachs | Chris Shibutani56% | $134 → $153 | Maintains | Buy | Get Alert |
| 01/23/2024 | Buy Now | — | Barclays | Carter Gould59% | $145 → $150 | Maintains | Overweight | Get Alert |
| 12/18/2023 | Buy Now | — | Stifel | Paul Matteis41% | $141 → $144 | Maintains | Buy | Get Alert |
| 12/13/2023 | Buy Now | — | Wells Fargo | Mohit Bansal70% | $110 → $127 | Maintains | Equal-Weight | Get Alert |
| 12/13/2023 | Buy Now | — | Citigroup | David Hoang35% | → $127 | Initiates | → Neutral | Get Alert |
| 12/12/2023 | Buy Now | — | Deutsche Bank | Neena Bitritto-Garg59% | → $136 | Initiates | → Buy | Get Alert |
| 12/07/2023 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni39% | → $150 | Reiterates | Buy → Buy | Get Alert |
| 11/10/2023 | Buy Now | — | BMO Capital | Evan Seigerman64% | $111 → $100 | Maintains | Market Perform | Get Alert |
| 11/10/2023 | Buy Now | — | RBC Capital | Brian Abrahams49% | $128 → $121 | Maintains | Sector Perform | Get Alert |
| 11/10/2023 | Buy Now | — | Mizuho | Uy Ear62% | $116 → $114 | Maintains | Neutral | Get Alert |
| 11/03/2023 | Buy Now | — | Mizuho | Uy Ear62% | $113 → $116 | Maintains | Neutral | Get Alert |
| 11/01/2023 | Buy Now | — | RBC Capital | Brian Abrahams49% | $123 → $128 | Maintains | Sector Perform | Get Alert |
| 11/01/2023 | Buy Now | — | Piper Sandler | David Amsellem70% | $95 → $100 | Maintains | Neutral | Get Alert |
| 11/01/2023 | Buy Now | — | Raymond James | Danielle Brill42% | $135 → $145 | Maintains | Outperform | Get Alert |
| 10/24/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan68% | — | Assumes | → Overweight | Get Alert |
| 10/06/2023 | Buy Now | — | Oppenheimer | Jay Olson61% | $160 → $165 | Maintains | Outperform | Get Alert |
| 10/06/2023 | Buy Now | — | HC Wainwright & Co. | Andrew Fein56% | $146 → $150 | Maintains | Buy | Get Alert |
| 09/13/2023 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni39% | $132 → $144 | Maintains | Buy | Get Alert |
| 09/13/2023 | Buy Now | — | Mizuho | Uy Ear62% | → $113 | Reiterates | Neutral → Neutral | Get Alert |
FAQ
What is the target price for Neurocrine Biosciences (NBIX) stock?
The latest price target for Neurocrine Biosciences (NASDAQ:NBIX) was reported by Evercore ISI Group on April 24, 2025. The analyst firm set a price target for $185.00 expecting NBIX to rise to within 12 months (a possible 72.24% upside). 69 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Neurocrine Biosciences (NBIX)?
The latest analyst rating for Neurocrine Biosciences (NASDAQ:NBIX) was provided by Evercore ISI Group, and Neurocrine Biosciences maintained their outperform rating.
When was the last upgrade for Neurocrine Biosciences (NBIX)?
The last upgrade for Neurocrine Biosciences Inc happened on April 15, 2025 when Needham raised their price target to $138. Needham previously had a hold for Neurocrine Biosciences Inc.
When was the last downgrade for Neurocrine Biosciences (NBIX)?
There is no last downgrade for Neurocrine Biosciences.
When is the next analyst rating going to be posted or updated for Neurocrine Biosciences (NBIX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurocrine Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurocrine Biosciences was filed on April 24, 2025 so you should expect the next rating to be made available sometime around April 24, 2026.
Is the Analyst Rating Neurocrine Biosciences (NBIX) correct?
While ratings are subjective and will change, the latest Neurocrine Biosciences (NBIX) rating was a maintained with a price target of $190.00 to $185.00. The current price Neurocrine Biosciences (NBIX) is trading at is $107.41, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
